



myMatrixx Delivers Advanced Clinical Expertise Backed by Powerful Data Insights

For One Leading Workers' Comp PBM, Robust Collaboration Between Clinical Pharmacists and Business Intelligence Has Led to Superior Claims Management in a Year Like No Other

Now more than ever, navigating the post-pandemic environment in workers' compensation pharmacy requires deep analysis of clinical data to improve outcomes and optimize claims goals. With presumption laws and the long-term effects of the disease becoming quickly emerging issues, successfully managing COVID-19 claims represents a major challenge ahead for the industry.

The next year and beyond will require a proactive approach, from monitoring new drug therapies to creating new formularies for COVID-19. In many situations, clinical pharmacists in workers' compensation require specialized insight when encountering a new type of drug therapy, or when an existing form of therapy is being used in a new way. For workers' compensation pharmacy benefit manager (PBM) myMatrixx, effective responses are built on our enhanced partnership between clinical and business intelligence teams.



Working together to understand new drug therapy trends

When the myMatrixx pharmacists began to observe an increase in anticoagulant usage, they immediately reached out to the data and analytics experts in the business intelligence division to gain insight. Says Chief Clinical Officer, **Phil Walls**, "When encountering new trends, workers' comp pharmacists face the task of piecing together disparate information. Increased access to data, such as the ability to leverage diagnostic information, is an important step that helps our profession make informed decisions."

Collecting and analyzing clinical data is essential to answering questions about pharmacy spending in 2021. According to **Cliff Belliveau**, Vice President of Business Intelligence, data analysis helps create actionable information. "Timely collection and deep analysis of relevant data provides our pharmacists with critical insight on the trends they're encountering," he explains. "After encountering an uptick in anticoagulant utilization, the clinical team needed clear information on a full range of patient data, including demographics, diagnosis, claim duration, comorbidities, and treatment history to really understand what was going on."



Isolating the data to gain actionable intelligence

In workers' compensation, anticoagulants are a specialty drug often used in the post-operative phase of orthopedic procedures to prevent blood clots. "By carefully analyzing clinical data, the myMatrixx clinical and business intelligence teams discovered that this recent increase appeared to be associated with work-related COVID-19 infections," says Belliveau.

This is a discovery with important implications for claims management going forward. "Traditionally, anticoagulants are a short-term drug for the rehabilitation phase of surgery. What we're seeing in many of these long-term COVID cases is extended use for a number of drug categories, and this anticoagulant utilization trend appears to fit this profile," says Walls.



Insights that move industry forward

As the industry works to understand the landscape of workers' compensation pharmacy into 2021, close collaboration between these two key components of pharmacy benefit management can help claims professionals make informed and strategic decisions.

Phil Walls will be presenting the latest findings from the annual **myMatrixx Drug Trend Report** in an upcoming R&I webinar that will be available on June 24, 2021. In that webinar, you will learn how the decrease in new workers' comp claims caused by the pandemic affected overall utilization statistics, and why opioid usage remains a concern by registering for this informative presentation.